Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
Omega Therapeutics (Nasdaq: OMGA), a pioneering biotechnology firm in mRNA therapeutics, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 11:30 a.m. GMT (6:30 a.m. ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Omega Therapeutics (Nasdaq: OMGA), a pioneering biotechnology firm in mRNA therapeutics, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 15, 2022, at 11:30 a.m. GMT (6:30 a.m. ET). A live webcast will be available on the company's website, with an archived replay accessible for 90 days. Omega is advancing its OMEGA Epigenomic Programming™ platform, targeting gene expression to tackle diseases across various areas, including oncology and immunology.
Details
News Market Reaction – OMGA
The recorded move for OMGA in the trading session of this news was -4.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 11:30 a.m. GMT (6:30 a.m. ET).
A live webcast of the fireside chat will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days.
Omega Therapeutics, founded by Flagship Pioneering, is a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines. The Company's OMEGA Epigenomic Programming™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth, and differentiation to cell death. Using a suite of technologies, paired with Omega's process of systematic, rational, and integrative drug design, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega's modular and programmable mRNA medicines, Omega Epigenomic Controllers™, target specific epigenomic loci within insulated genomic domains, EpiZips, from amongst thousands of unique, mapped, and validated genome-wide DNA-sequences, with high specificity to durably tune single or multiple genes to treat and cure diseases through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.
Contacts
Investor contact:
Eva Stroynowski
Omega Therapeutics
617.949.4370
estroynowski@omegatx.com
Media contact:
Jason Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-301666519.html
SOURCE Omega Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.